Document Detail

HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.
MedLine Citation:
PMID:  10559508     Owner:  NLM     Status:  MEDLINE    
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase (statins) may enhance vascular endothelial function independent of their cholesterol lowering effect. To test this hypothesis, we surveyed two groups of patients (age 55+/-7, mean+/-SD) with coronary artery disease that were matched for age, blood pressure and serum lipid levels. Group 1 comprised 23 men without lipid-lowering medication and Group 2 included 22 patients with ongoing HMG CoA reductase inhibitor medication. Flow-mediated (endothelium-dependent) arterial dilatation (FMD) and nitrate-mediated (smooth muscle dependent) dilatation (NMD) were measured in the brachial artery using high resolution ultrasound. FMD was considerably higher in group 2 (4.3+/-2.6 vs. 2.6+/-2.8%; P<0.05). In multivariate regression model, statin use was the only significant (P<0.05) predictor of FMD. In all subjects, FMD correlated with statin dose (P<0.05 for trend). NMD was non-significantly higher in group 2 (11.4+/-5.0 vs. 9.0+/-4.2%, P=0. 08). We conclude that patients with established coronary artery disease on HMG CoA reductase inhibitor therapy have better vascular endothelial function than similar patients without the medication. These data provide further support for the idea that HMG CoA reductase inhibitors enhance endothelial function independent of their lipid-lowering effects. This may suggest that these drugs could be beneficial in secondary prevention of coronary artery disease regardless of the serum cholesterol concentration.
M J Järvisalo; J O Toikka; T Vasankari; J Mikkola; J S Viikari; J J Hartiala; O T Raitakari
Related Documents :
15770338 - New trends in lipid management: eight cases to consider.
2787708 - Relative impact of targeted versus populationwide cholesterol interventions on the inci...
176718 - Serum beta-lipoprotein subfractions in polyacrylamide gel electrophoresis associated wi...
20043338 - The efficacy of statin therapy in patients with acute coronary syndromes and concomitan...
6255848 - Calcium channel blocking agents in the treatment of cardiovascular disorders. part i: b...
8960448 - Angina and left ventricular dysfunction.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Atherosclerosis     Volume:  147     ISSN:  0021-9150     ISO Abbreviation:  Atherosclerosis     Publication Date:  1999 Dec 
Date Detail:
Created Date:  2000-01-06     Completed Date:  2000-01-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  237-42     Citation Subset:  IM    
Department of Clinical Physiology, Turku University Central Hospital, Turku, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Cholesterol, HDL / blood,  drug effects
Cholesterol, LDL / blood,  drug effects
Coronary Angiography
Coronary Disease / drug therapy*,  radiography,  ultrasonography
Coronary Vessels / drug effects*,  pathology
Cross-Sectional Studies
Endothelium, Vascular / drug effects*,  physiology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Linear Models
Middle Aged
Multivariate Analysis
Reference Values
Vascular Patency
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fractional efflux and net change in cellular cholesterol content mediated by sera from mice expressi...
Next Document:  Influence of serum triglyceride levels on the risk for myocardial infarction in 12,510 middle aged m...